For the first time, the World Health Organization has added various high-cost treatments for diabetes and cystic fibrosis to its list of essential medicines, a move that patient advocates hope will usher in a new era of more accessible drugs to countless people in low- and middle-income countries.
First published in 1977, the list is used by governments as a guide to improving supply chains and controlling costs. In years past, adding a drug has helped boost access for people in lower-income countries, such as for HIV treatments in the early 2000s. The list has been adopted in more than 150 countries and now includes a total of 523 essential medicines for adults and 374 for children.
The latest version added Eli Lilly’s Mounjaro and Novo Nordisk’s Ozempic to treat type 2 diabetes in conjunction with cardiovascular disease, chronic kidney disease, or obesity. Both drugs belong to a class of medicines known as GLP-1s. The same companies also sell two other such drugs that have been approved by health regulators for combating obesity.
STAT+ Exclusive Story
Already have an account? Log in
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in
Individual plans
Group plans
To read the rest of this story subscribe to STAT+.